WGS for B16-OVA and 4T1 murine cancer cell lines

ABSTRACT: Whole Genome Sequencing of the murine breast cancer cell line 4T1 and of the murine melanoma cell line B16-ova was carried out with the aim of identifying somatic mutations. We also ran deep Mass Spectrometry proteomics analysis on the same cell lines, aiming to determine which somatic mutations carry over to the protein expression level. Further, we tested these cancer specific protein epitopes (putative neoantigens) for immunogenicity using mouse models. Finally, the putative neoantigens that showed good immunogenic potential were used in tumor growth control experiments with mice engrafted with the two tumor cell lines. In these experiments we tested whether cancer vaccines based on individual neoantigen peptides (MHC-I) restricted the growth of the tumor compared to adequate controls.

INSTRUMENT(S): Illumina HiSeq X

ORGANISM(S): Mus musculus

SUBMITTER: Rui Miguel Mamede Branca 

PROVIDER: E-MTAB-13635 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress